Pharmacological profiles in rats of novel antipsychotics with combined dopamine D2/serotonin 5-HT1A activity

Comparison with typical and atypical conventional antipsychotics

Laurent Bardin, Agnès Auclair, Mark S. Kleven, Eric P M Prinssen, Wouter Koek, Adrian Newman-Tancredi, Ronan Depoortère

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

Original languageEnglish
Pages (from-to)103-118
Number of pages16
JournalBehavioural Pharmacology
Volume18
Issue number2
DOIs
StatePublished - Mar 2007

Fingerprint

Antipsychotic Agents
Receptor, Serotonin, 5-HT1A
Dopamine
Serotonin
Pharmacology
Catalepsy
Methylphenidate
Dopamine D2 Receptors
Dopamine Agonists
Ketamine
Amphetamine

ASJC Scopus subject areas

  • Pharmacology
  • Neuroscience(all)

Cite this

Pharmacological profiles in rats of novel antipsychotics with combined dopamine D2/serotonin 5-HT1A activity : Comparison with typical and atypical conventional antipsychotics. / Bardin, Laurent; Auclair, Agnès; Kleven, Mark S.; Prinssen, Eric P M; Koek, Wouter; Newman-Tancredi, Adrian; Depoortère, Ronan.

In: Behavioural Pharmacology, Vol. 18, No. 2, 03.2007, p. 103-118.

Research output: Contribution to journalArticle

Bardin, Laurent ; Auclair, Agnès ; Kleven, Mark S. ; Prinssen, Eric P M ; Koek, Wouter ; Newman-Tancredi, Adrian ; Depoortère, Ronan. / Pharmacological profiles in rats of novel antipsychotics with combined dopamine D2/serotonin 5-HT1A activity : Comparison with typical and atypical conventional antipsychotics. In: Behavioural Pharmacology. 2007 ; Vol. 18, No. 2. pp. 103-118.
@article{6da027d6db5a4bfabbf53290639bf9b8,
title = "Pharmacological profiles in rats of novel antipsychotics with combined dopamine D2/serotonin 5-HT1A activity: Comparison with typical and atypical conventional antipsychotics",
abstract = "Combining antagonist/partial agonist activity at dopamine D2 and agonist activity at serotonin 5-HT1A receptors is one of the approaches that has recently been chosen to develop new generation antipsychotics, including bifeprunox, SSR181507 and SLV313. There have been, however, few comparative data on their pharmacological profiles. Here, we have directly compared a wide array of these novel dopamine D2/5-HT1A and conventional antipsychotics in rat models predictive of antipsychotic activity. Potency of antipsychotics to antagonize conditioned avoidance, methylphenidate-induced behaviour and D-amphetamine-induced hyperlocomotion correlated with their affinity at dopamine D2 receptors. Potency against ketamine-induced hyperlocomotion was independent of affinity at dopamine D2 or 5-HT1A receptors. Propensity to induce catalepsy, predictive of occurrence of extrapyramidal side effects, was inversely related to affinity at 5-HT1A receptors. As a result, preferential D2/5-HT1A antipsychotics displayed a large separation between doses producing 'antipsychotic-like' vs. cataleptogenic actions. These data support the contention that 5-HT1A receptor activation greatly reduces or prevents the cataleptogenic potential of novel antipsychotics. They also emphasize that interactions at 5-HT1A and D2 receptors, and the nature of effects (antagonism or partial agonism) at the latter has a profound influence on pharmacological activities, and is likely to affect therapeutic profiles.",
keywords = "5-HT receptors, Antipsychotics, Catalepsy, Conditioned avoidance response, D-amphetamine, Dopamine D receptors, Methylphenidate, Rat",
author = "Laurent Bardin and Agn{\`e}s Auclair and Kleven, {Mark S.} and Prinssen, {Eric P M} and Wouter Koek and Adrian Newman-Tancredi and Ronan Depoort{\`e}re",
year = "2007",
month = "3",
doi = "10.1097/FBP.0b013e3280ae6c96",
language = "English",
volume = "18",
pages = "103--118",
journal = "Behavioural Pharmacology",
issn = "0955-8810",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Pharmacological profiles in rats of novel antipsychotics with combined dopamine D2/serotonin 5-HT1A activity

T2 - Comparison with typical and atypical conventional antipsychotics

AU - Bardin, Laurent

AU - Auclair, Agnès

AU - Kleven, Mark S.

AU - Prinssen, Eric P M

AU - Koek, Wouter

AU - Newman-Tancredi, Adrian

AU - Depoortère, Ronan

PY - 2007/3

Y1 - 2007/3

N2 - Combining antagonist/partial agonist activity at dopamine D2 and agonist activity at serotonin 5-HT1A receptors is one of the approaches that has recently been chosen to develop new generation antipsychotics, including bifeprunox, SSR181507 and SLV313. There have been, however, few comparative data on their pharmacological profiles. Here, we have directly compared a wide array of these novel dopamine D2/5-HT1A and conventional antipsychotics in rat models predictive of antipsychotic activity. Potency of antipsychotics to antagonize conditioned avoidance, methylphenidate-induced behaviour and D-amphetamine-induced hyperlocomotion correlated with their affinity at dopamine D2 receptors. Potency against ketamine-induced hyperlocomotion was independent of affinity at dopamine D2 or 5-HT1A receptors. Propensity to induce catalepsy, predictive of occurrence of extrapyramidal side effects, was inversely related to affinity at 5-HT1A receptors. As a result, preferential D2/5-HT1A antipsychotics displayed a large separation between doses producing 'antipsychotic-like' vs. cataleptogenic actions. These data support the contention that 5-HT1A receptor activation greatly reduces or prevents the cataleptogenic potential of novel antipsychotics. They also emphasize that interactions at 5-HT1A and D2 receptors, and the nature of effects (antagonism or partial agonism) at the latter has a profound influence on pharmacological activities, and is likely to affect therapeutic profiles.

AB - Combining antagonist/partial agonist activity at dopamine D2 and agonist activity at serotonin 5-HT1A receptors is one of the approaches that has recently been chosen to develop new generation antipsychotics, including bifeprunox, SSR181507 and SLV313. There have been, however, few comparative data on their pharmacological profiles. Here, we have directly compared a wide array of these novel dopamine D2/5-HT1A and conventional antipsychotics in rat models predictive of antipsychotic activity. Potency of antipsychotics to antagonize conditioned avoidance, methylphenidate-induced behaviour and D-amphetamine-induced hyperlocomotion correlated with their affinity at dopamine D2 receptors. Potency against ketamine-induced hyperlocomotion was independent of affinity at dopamine D2 or 5-HT1A receptors. Propensity to induce catalepsy, predictive of occurrence of extrapyramidal side effects, was inversely related to affinity at 5-HT1A receptors. As a result, preferential D2/5-HT1A antipsychotics displayed a large separation between doses producing 'antipsychotic-like' vs. cataleptogenic actions. These data support the contention that 5-HT1A receptor activation greatly reduces or prevents the cataleptogenic potential of novel antipsychotics. They also emphasize that interactions at 5-HT1A and D2 receptors, and the nature of effects (antagonism or partial agonism) at the latter has a profound influence on pharmacological activities, and is likely to affect therapeutic profiles.

KW - 5-HT receptors

KW - Antipsychotics

KW - Catalepsy

KW - Conditioned avoidance response

KW - D-amphetamine

KW - Dopamine D receptors

KW - Methylphenidate

KW - Rat

UR - http://www.scopus.com/inward/record.url?scp=33947148162&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33947148162&partnerID=8YFLogxK

U2 - 10.1097/FBP.0b013e3280ae6c96

DO - 10.1097/FBP.0b013e3280ae6c96

M3 - Article

VL - 18

SP - 103

EP - 118

JO - Behavioural Pharmacology

JF - Behavioural Pharmacology

SN - 0955-8810

IS - 2

ER -